Company profile
Zenas BioPharma, Inc.
NASDAQ: ZBIO · Healthcare · Biotechnology
#633 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
33DFH 33DQ 27GM —SS 54
v0.1 · 55/100 weight · provisional
↑ market scale, revenue growth (YoY) · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$1.0M
Rev growth YoY (TTM)
-93.3%
Net income (FY)
-$377.7M
Employees
167
as of 2026-08-10
Market cap
$2.0B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$10.0M$10.0M2025
Net income-$377.7M-$377.7M2025
Operating income-$383.1M-$383.1M2025
Total assets$383.6M$383.6M2025
Liabilities$141.5M$141.5M2025
Equity$242.1M$242.1M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Zenas BioPharma, Inc.’s revenue?
Zenas BioPharma, Inc. booked $10.0M in FY2025 revenue, growing 100% year over year — faster than most Healthcare companies we track, at a -3777.4% net margin.
Peers · Healthcare
TScan Therapeutics, Inc.39DAlpha Cognition Inc39DKhiron Life Sciences Corp.——Janux Therapeutics, Inc.54DSyros Pharmaceuticals, Inc.——Stablecoin Development Corp.44DNeighbors
Middlesex →Key facts
CEOLeon Oliver Moulder Jr.
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: ZBIO
Employees167
IPO date2024-09-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.